Analyst Price Targets — TRDA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 11:16 am | — | Guggenheim | $17.00 | $6.37 | TheFly | Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim |
| May 8, 2026 5:02 pm | — | Roth Capital | $10.00 | $6.63 | TheFly | Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital |
| February 10, 2026 9:19 pm | — | Guggenheim | $20.00 | $10.82 | TheFly | Entrada Therapeutics initiated with a Buy at Guggenheim |
| January 28, 2026 12:34 pm | Kostas Biliouris | Oppenheimer | $21.00 | $11.00 | TheFly | Entrada Therapeutics initiated with an Outperform at Oppenheimer |
| November 6, 2025 11:37 pm | — | Roth Capital | $13.00 | $6.95 | TheFly | Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital |
| February 28, 2025 1:18 pm | — | Roth Capital | $23.00 | $11.94 | TheFly | Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM |
| November 6, 2024 11:41 am | Boobalan Pachaiyappan | H.C. Wainwright | $20.00 | $18.03 | StreetInsider | Entrada Therapeutics (TRDA) PT Raised to $20 at H.C. Wainwright |
| June 25, 2024 6:24 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $14.24 | TheFly | Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright |
Latest News for TRDA
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight…
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRDA.
U.S. House Trading
No House trades found for TRDA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.